It is safe to claim that the gap between the treatment of allergic conjunctivitis and the therapy of dry eye illness is narrower than it has ever been. Although the 2 diseases have different pathophysiologies, etiologies, and demographics of individuals who are affected by them, the treatments for the 2 diseases overlap more than ever before.

Reproxalap for dry eye disease

Reproxalap (Aldeyra Therapeutics, Inc.) is a novel therapeutic candidate under research for the treatment of dry eye disease.¹ It is a first-of-its-kind small molecule modulator of reactive aldehyde species (RASP), which is increased in inflammatory diseases of the body, including the eyes. Malondialdehyde (MDA), the most well-known RASP, has been linked to inflammatory ocular conditions such as autoimmune disorders, allergic conjunctivitis, and dry eye disease…..

Read more: https://www.optometrytimes.com/view/ocular-allergies-and-dry-eye-disease-overlapping-treatment-options?utm_source=sfmc&utm_medium=email&utm_campaign=09092023_OD_ESS-23-OTD0379_eNL_Essilor_EyeCon%20House%20ad&eKey=ZG9ubmFAbWFjdWxhcmhvcGUub3Jn

Source: Opotometry Times